In response to the etiology and pathogenesis of NASH, several medical treatments with different targets are being tested in clinical trials, including peroxisome proliferator-activated receptors (PPARs) agonists like saroglitazar and pioglitazone7, farnesoid X receptor(FXR) agonist obeticholic acid (OCA)8 and glucagon-like peptide-1 receptor (GLP1R) agonists and its analogs9. Here, GLP1R is linked to metabolic dysfunction-associated steatohepatitis.